ContractOncoMed Pharmaceuticals Inc • March 10th, 2016 • Pharmaceutical preparations • California
[DATE] [NAME] [ADDRESS] Re: Amended and Restated Change in Control and Severance Agreement Dear [NAME]: You and OncoMed Pharmaceuticals, Inc. (the “Company”) are parties to a Change in Control and Severance Agreement dated [_____________] (the “Change in Control Agreement”), which sets forth, among other things, the terms and conditions of certain severance benefits payable to you in the event of a qualifying termination of your employment. This letter (this “Agreement”) amends and restates the Change in Control Agreement to provide you with additional benefits in the event of certain terminations of your employment. This Agreement supersedes the Change in Control Agreement and any other agreement or policy to which the Company is a party with respect to the cessation of your employment with the Company. 1. Definitions. For purposes of the Agreement, the following terms shall have their respective meanings set forth below: (a) “Cause” shall mean any of the following: (i) your intention
AMENDMENT 3 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • March 10th, 2016 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment 3 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into on November 4, 2015 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractOffer Letter Agreement • March 10th, 2016 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • California
October 12, 2015 Mr. Paul Hastings 61 Hartford Street San Francisco, CA 94114 Re: Change in Control and Severance Agreement Dear Paul: You and OncoMed Pharmaceuticals, Inc. (the “Company”) are parties to an offer letter dated November 12, 2005, as amended by the Amendment to Employment Agreement dated July 2, 2013 (the “Offer Letter Agreement”), which sets forth, among other things, the terms and conditions of certain severance benefits payable to you in the event of a qualifying termination of your employment. This letter (this “Agreement”) provides you with additional benefits in the event of certain terminations of your employment. This Agreement supersedes the change in control and severance provisions of your Offer Letter Agreement and any other agreement or policy to which the Company is a party with respect to the cessation of your employment with the Company. All other provisions of your Offer Letter Agreement shall remain in full force and effect. 1. Definitions. For purposes
